Want to see KMTS full AI Analyst Report?
KMTS Stock Chart & Stats
$21.06
$1.80(8.55%)
At close: 4:00 PM EDT
$21.06
$1.80(8.55%)
Day’s Range― - ―
52-Week Range$14.30 - $30.00
Previous CloseN/A
Volume51.18K
Average Volume (3M)310.69K
Market Cap
$1.34B
Enterprise Value$1.06K
Total Cash (Recent Filing)$196.43M
Total Debt (Recent Filing)$4.14M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Sep 10, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding58,603,123
10 Day Avg. Volume502,173
30 Day Avg. Volume310,694
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.66
Price to Sales (P/S)12.72
P/FCF Ratio-10.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside42.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$136.98M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Prescription MomentumRapid, sustained revenue and prescription gains indicate expanding clinical adoption and recurring service demand. Scaling prescriptions and territory growth (from ~80 to ~130) supports durable revenue per patient, strengthens payer relationships, and underpins predictable long-term service volumes.
Gross Margin Expansion & Unit EconomicsMaterial, multi-quarter gross margin improvement demonstrates improving unit economics. Progress toward management's 70%+ margin target through higher in-network mix, RCM improvements and AI detection reduces required break-even volumes and makes sustainable profits more reliant on operating leverage than sheer volume.
Strong Liquidity And Low DebtSubstantial cash/investments plus a secured term facility give multi-quarter runway without immediate dilution. Combined with very modest reported debt (~$4.1M vs equity ~$259.7M), this balance sheet optionality supports ongoing commercial expansion, RCM investments and potential M&A while preserving strategic flexibility.
Bears Say
Persistent Cash Burn And Negative FCFConsistently negative operating cash flow and deeply negative free cash flow mean the business consumes significant capital as it scales. Persistent cash burn elevates refinancing and dilution risk if revenue growth or margin improvements underperform, constraining long-term capital allocation and strategic optionality.
Large Operating LossesVery large operating losses and highly negative net margins indicate scale has not yet converted to profitability. Sustained negative EBIT undermines return metrics and means management must deliver material margin and RCM improvements to achieve durable, shareholder-friendly cash generation over the medium term.
Execution & Market Penetration RiskAn underpenetrated market creates opportunity but requires flawless execution. Conversion variability (~46%), rep ramp times (~6 months) and competitor/regulatory activity create structural execution risk that could slow adoption, increase customer acquisition cost, and pressure the company’s ability to realize projected durable market share gains.
Kestra Medical Technologies Ltd. News
KMTS FAQ
What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?
Kestra Medical Technologies Ltd. lowest stock price was $14.30 and its highest was $30.00 in the past 12 months.
What is Kestra Medical Technologies Ltd.’s market cap?
Kestra Medical Technologies Ltd.’s market cap is $1.34B.
When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?
Kestra Medical Technologies Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 32 days.
How were Kestra Medical Technologies Ltd.’s earnings last quarter?
Kestra Medical Technologies Ltd. released its earnings results on Jul 14, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.08.
Is Kestra Medical Technologies Ltd. overvalued?
According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued.
Does Kestra Medical Technologies Ltd. pay dividends?
Kestra Medical Technologies Ltd. does not currently pay dividends.
What is Kestra Medical Technologies Ltd.’s EPS estimate?
Kestra Medical Technologies Ltd.’s EPS estimate is -0.62.
How many shares outstanding does Kestra Medical Technologies Ltd. have?
Kestra Medical Technologies Ltd. has 58,603,123 shares outstanding.
What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?
Kestra Medical Technologies Ltd. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 1.799%.
Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?
Currently, no hedge funds are holding shares in KMTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kestra Medical Technologies Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (42.45% Upside)
$30.00 (42.45% Upside)
Blogger Sentiment
Bullish
KMTS Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 652.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.21%
Trailing 12-Months
Company Description
Kestra Medical Technologies Ltd.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
KMTS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized robust top-line momentum (66% Q4 revenue growth, 59% FY growth), meaningful gross margin expansion (10+ percentage points QoQ/Yoy improvements), strong clinical validation (ACE-PAS study and publication), and reinforced liquidity via a $200M term loan — all supportive of durable long-term growth. Offsetting these positives are ongoing negative adjusted EBITDA, elevated operating investments (material increases in operating expense excluding nonrecurring items), and short-term phasing risks from rapid hiring and rep ramp-up. Management framed the expense growth as deliberate investment to capture a large underpenetrated market and expects operating leverage to improve over the next several years.View all KMTS earnings summariesKMTS Stock 12 Month Forecast
Average Price Target
$30.00
▲(42.45% Upside)
Technical Analysis
Ownership Overview
47.88% Insiders
26.37% Mutual Funds
4.75% Other Institutional Investors
15.04% Public Companies and
Individual Investors